The global pegfilgrastim biosimilars market size was valued at USD 0.54 million in 2022 and is projected to grow at a CAGR of 7% during the forecast period of 2023-2031. The market growth can be attributed to the increasing prevalence of cancer, a growing geriatric population, and the rising demand for affordable cancer therapies.
Asia Pacific is another region experiencing significant growth in the pegfilgrastim biosimilars market. The region's market growth is driven by factors such as a large population base, increasing cancer incidence, and growing healthcare expenditure. In addition, government initiatives to improve healthcare infrastructure and support the development of biosimilars are helping to drive the growth of the market in the region.
Global Pegfilgrastim Biosimilars Market: Introduction
Pegfilgrastim biosimilars are biologically similar versions of the reference pegfilgrastim product, which is used to stimulate the growth of white blood cells to help reduce the risk of infection during cancer treatment. These biosimilars have demonstrated comparable safety and efficacy to the reference product but are typically available at a lower cost, making them an attractive option for healthcare systems and patients. The increasing prevalence of cancer, coupled with the growing demand for cost-effective cancer treatments, is driving the demand for pegfilgrastim biosimilars. Other factors, such as the expiration of key patents and the development of robust regulatory frameworks, are also expected to drive market growth.Pegfilgrastim Biosimilars Market Segmentations
The market can be segmented based on indication, product type, application, distribution channel, and region:Market Breakup by Indication Type
- Neutropenia
- Hematopoietic Subsyndrome
- Others
Market Breakup by Product Type
- MK-6302
- Peg G-CSF
- PEG Neutrogena
- Grasustek
- LA-EP2006
- R-TPR-029
- Filgrastim
- PEG-GCSF
- Others
Market Breakup by Application
- Chemotherapy Induced Neutropenia
- Transplantation
- Others
Market Breakup by Distribution Channel
- Hospital Based Pharmacies
- Online Pharmacies
- Retail Pharmacies
Market Breakup by Region
North America
- United States of America
- Canada
Europe
- United Kingdom
- Germany
- France
- Italy
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Pegfilgrastim Biosimilars Market Analysis
The global pegfilgrastim biosimilars market has experienced significant growth over the past few years, driven by factors such as the increasing prevalence of cancer, the growing geriatric population, and the rising demand for cost-effective cancer therapies. North America is currently the largest market for pegfilgrastim biosimilars, driven by factors such as the high prevalence of cancer, a well-established healthcare infrastructure, and strong investments in research and development. Additionally, the growing adoption of biosimilars and supportive regulatory frameworks are further driving the growth of the market in North America.Asia Pacific is another region experiencing significant growth in the pegfilgrastim biosimilars market. The region's market growth is driven by factors such as a large population base, increasing cancer incidence, and growing healthcare expenditure. In addition, government initiatives to improve healthcare infrastructure and support the development of biosimilars are helping to drive the growth of the market in the region.
Key Players in the Global Pegfilgrastim Biosimilars Market
The report provides a detailed analysis of the key players involved in the pegfilgrastim biosimilars market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:- Merck & Co., Inc
- Zydus Lifesciences Limited
- Ratiopharm GmbH
- Jiangsu Hengrui Pharmaceuticals Co. Ltd
- Biocon Limited
- Dr. Reddy's Laboratories Ltd
- Pfizer Inc
- Emcure Pharmaceuticals Limited
- USV Private Limited
- Apotex Pty Ltd
- Kyowa Kirin Co., Ltd
- Lupin Limited
Table of Contents
1 Preface
4 Pegfilgrastim Biosimilars Overview
5 Patient Profile
6 Current Scenario Evaluation and Regulatory Framework
7 Challenges and Unmet Needs
8 Global Pegfilgrastim Biosimilars Market
9 North America Pegfilgrastism Biosimilar Market
10 Europe Pegfilgrastism Biosimilar Market
11 Asia Pacific Pegfilgrastism Biosimilar Market
12 Latin America Pegfilgrastism Biosimilar Market
13 Middle East and Africa Pegfilgrastism Biosimilar Market
14 Global Pegfilgrastim Biosimilars Market Dynamics
15 Supplier Landscape
16 Pricing Models and Strategies (Additional Insight)
17 Global Pegfilgrastim Biosimilars Distribution Model (Additional Insight)
Companies Mentioned
- Merck & Co., Inc.
- Zydus Lifesciences Limited
- Ratiopharm GmbH
- Jiangsu Hengrui Pharmaceuticals Co. Ltd
- Biocon Limited
- Dr. Reddy's Laboratories Ltd
- Pfizer Inc.
- Emcure Pharmaceuticals Limited
- USV Private Limited
- Apotex Pty Ltd
- Kyowa Kirin Co., Ltd.
- Lupin Limited
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 147 |
| Published | March 2023 |
| Forecast Period | 2023 - 2031 |
| Estimated Market Value ( USD | $ 0.58 Million |
| Forecasted Market Value ( USD | $ 0.99 Million |
| Compound Annual Growth Rate | 7.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
Related Reports
Pegfilgrastim Biosimilars Global Market Report 2024
- Report
- 250 Pages
- Global
From
Biosimilar Market Report by Molecule, Indication, Manufacturing Type, and Region 2024-2032
- Report
- 145 Pages
- Global
From
Filgrastim Biosimilars Market Report 2024
- Report
- 250 Pages
- Global
From
Biosimilars - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029
- Report
- 116 Pages
- Global
From
This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a market research report. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF. This product is a market research report. This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF. 
